DDAB:DOPE (50:50) Liposomes - Creative Biolabs

FAQs Published Data Customer Reviews Related Sections

What are DDAB:DOPE (50:50) liposomes and what is their primary use in research?
DDAB:DOPE (50:50) liposomes are cationic liposomes formed by the combination of DDAB (Dimethyldioctadecylammonium bromide) and DOPE (Dioleoylphosphatidylethanolamine) in a 1:1 molar ratio. These liposomes are primarily used for the delivery of genetic materials such as DNA, RNA, siRNA, and other nucleic acids into cells. Their positive charge aids in the efficient encapsulation and cellular uptake of negatively charged genetic materials.
How do DDAB:DOPE (50:50) liposomes enhance gene delivery compared to other delivery systems?
The cationic nature of DDAB:DOPE (50:50) liposomes facilitates the formation of complexes with negatively charged nucleic acids, improving encapsulation efficiency and protection of the genetic material from degradation. Additionally, the presence of DOPE, a fusogenic lipid, enhances the fusion of liposomes with cell membranes, promoting efficient intracellular delivery of the encapsulated nucleic acids.
What are the key characteristics of DDAB:DOPE (50:50) liposomes that researchers should consider?
Key characteristics include the size distribution, zeta potential, and encapsulation efficiency of the liposomes. The mean particle size is typically 100 nm, which is optimal for cellular uptake. The zeta potential indicates the surface charge, crucial for forming stable complexes with genetic material. Encapsulation efficiency determines the amount of nucleic acid that can be successfully loaded into the liposomes.
Can DDAB:DOPE (50:50) liposomes be used for in vivo experiments?
While primarily designed for in vitro research applications, DDAB:DOPE (50:50) liposomes can also be used for in vivo studies. Researchers must carefully consider factors such as biodistribution, clearance rates, and potential immunogenicity. It is recommended to perform thorough preliminary studies to assess the feasibility and safety of using these liposomes in vivo.
How can the efficiency of gene delivery using DDAB:DOPE (50:50) liposomes be optimized?
Efficiency can be optimized by adjusting the ratio of liposomes to nucleic acids, incubation time, and the conditions of the cell culture medium. It is also important to fine-tune the liposome formulation by altering the lipid composition or incorporating additional components that can enhance cellular uptake and endosomal escape. Empirical testing is essential to determine the most effective conditions for each specific application.

DDAB:DOPE (50:50) Liposomes-fig1

Biodistribution of Cy5.5-siRNA at 1 h after intravenous administration by cationic lipoplexes into mice with lung-metastasized MCF-7-Luc tumor

The study focuses on employing cationic liposomes, specifically DDAB:DOPE (50:50) formulations, for delivering siRNA to lung metastasis from breast tumors. The significance of cationic liposomes in siRNA delivery arises from their efficiency in intravenous injections, facilitating gene silencing in lung-metastasized tumors. This approach uses 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or dimethyldioctadecylammonium bromide (DDAB) combined with cholesterol or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as the lipid components. The study's results revealed that DDAB/DOPE lipoplexes, among others tested, did not induce gene silencing in in vivo experiments, highlighting a distinct difference between in vitro and in vivo efficacy. Despite this, DDAB/DOPE lipoplexes effectively suppressed luciferase activity in vitro. The investigation into intracellular localization and biodistribution patterns of siRNA delivered via these lipoplexes showed a preferential accumulation in the lungs, with DOTAP-based formulations being more effective in inducing gene silencing in lung-metastasized tumors. This work underlines the potential of DOTAP-based liposomes as in vivo siRNA delivery carriers for targeting lung metastases, pointing to the critical role of lipid composition in optimizing therapeutic gene delivery strategies

Hattori, Y., Nakamura, A., et al. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. Journal of liposome research. 2015, 25(4): 279-286.

Unmatched Performance in RNA Delivery
Utilizing DDAB:DOPE (50:50) liposomes from Creative Biolabs transformed our RNA-based therapies research. The superior encapsulation and delivery rates are unmatched, underscoring their pivotal role in advancing RNA therapeutics.
Benchmark for Vaccine Formulation Studies
In the realm of vaccine formulation, Creative Biolabs' DDAB:DOPE liposomes set a high benchmark. Their stability and biocompatibility are exceptional, providing reliable results in our most critical studies.
Elevating Drug Development Processes
DDAB:DOPE (50:50) liposomes have elevated our drug development processes to new heights. Their formulation ensures targeted delivery and release, crucial for the success of next-generation pharmaceuticals.
Gold Standard in Liposome Research
Among peers, Creative Biolabs' DDAB:DOPE (50:50) liposomes are the gold standard. Their consistent performance and quality in drug delivery applications make them a preferred choice for researchers worldwide.
Pioneering Solutions for Nucleic Acid Delivery
The versatility of DDAB:DOPE liposomes in nucleic acid delivery is unparalleled. Their use has led to groundbreaking findings in gene therapy research, making them an indispensable tool for innovative studies.

Click the button below to contact us or submit your feedback about this product.

DDAB:DOPE (50:50) Liposomes (CAT#: LDLY-0123-LY184)